Der Nephrologe

, Volume 8, Issue 2, pp 128–135

Abschätzung des kardiovaskulären Risikos

Bedeutung renaler Parameter
Leitthema
  • 208 Downloads

Zusammenfassung

Der SCORE wird von der Europäischen Gesellschaft für Kardiologie zur Berechnung des Mortalitätsrisikos über einen Zeitraum von 10 Jahren bei asymptomatischen Erwachsenen empfohlen. Er berücksichtigt die Risikofaktoren Alter, Geschlecht, systolischer Blutdruck, Cholesterin und Rauchen. Das so bestimmte Risiko ist aber nicht immer hinreichend präzise und wird durch die Berücksichtigung renaler Variablen prognostisch erheblich aufgewertet. Im diesem Kontext von besonderer Bedeutung ist sowohl die errechnete glomeruläre Filtrationsrate als auch die Albuminausscheidung im Urin. Für beide Parameter lässt sich eine Steigerung in der Abschätzung des Risikos unabhängig von der eigentlichen SCORE-Klassifizierung belegen. Sie führt oberhalb eines Risikos von 1% zu einer Zuordnung der Patienten zur nächsthöheren Risikostufe im SCORE.

Schlüsselwörter

Mortalitätrisiko Risikofaktoren SCORE Albuminurie Glomeruläre Filtrationsrate 

Estimation of cardiovascular risk

Importance of renal parameters

Abstract

The SCORE classification is recommended by the European Society of Cardiology to calculate the mortality risk over a period of 10 years in asymptomatic adults. It takes into account the risk factors of age, gender, systolic blood pressure, cholesterol and smoking, however, the determined risk is not always sufficiently precise and its prognostic performance is improved by considering renal variables. In this context the estimated glomerular filtration rate and urinary albumin excretion are of particular importance. For both parameters an incremental increase in risk regardless of the actual SCORE classification was shown and above a risk of 1% leads to an assignment of the patient to the next level of risk in the SCORE.

Keywords

Mortality risk Risk factors SCORE Albuminuria Glomerular filtration rate 

Literatur

  1. 1.
    Apperloo AJ, De Zeeuw D, De Jong PE (1997) A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 51:793–797PubMedCrossRefGoogle Scholar
  2. 2.
    Atkins RC, Briganti EM, Lewis JB et al (2005) Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 45:281–287PubMedCrossRefGoogle Scholar
  3. 3.
    Barnett AH, Bain SC, Bouter P et al (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351:1952–1961PubMedCrossRefGoogle Scholar
  4. 4.
    Brugts JJ, Knetsch AM, Mattace-Raso FU et al (2005) Renal function and risk of myocardial infarction in an elderly population: the Rotterdam Study. Arch Intern Med 165:2659–2665PubMedCrossRefGoogle Scholar
  5. 5.
    Chronic Kidney Disease Prognosis Cosortium; Matsushita K, van der Velde M, Astor BC et al (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375:2073–2081CrossRefGoogle Scholar
  6. 6.
    De Zeeuw D, Remuzzi G, Parving HH et al (2004) Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110:921–927CrossRefGoogle Scholar
  7. 7.
    Di Angelantonio E, Danesh J, Eiriksdottir G et al (2007) Renal function and risk of coronary heart disease in general populations: new prospective study and systematic review. PLoS Med 4:e270CrossRefGoogle Scholar
  8. 8.
    Gaede P, Lund-Andersen H, Parving HH et al (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580–591PubMedCrossRefGoogle Scholar
  9. 9.
    Gerstein HC, Mann JF, Yi Q et al (2001) Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421–426PubMedCrossRefGoogle Scholar
  10. 10.
    Go AS, Chertow GM, Fan D et al (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305PubMedCrossRefGoogle Scholar
  11. 11.
    Henry RM, Kostense PJ, Bos G et al (2002) Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 62:1402–1407PubMedCrossRefGoogle Scholar
  12. 12.
    Hillege HL, Fidler V, Diercks GF et al (2002) Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106:1777–1782PubMedCrossRefGoogle Scholar
  13. 13.
    Holtkamp FA, De Zeeuw D, Thomas MC et al (2011) An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 80:282–287PubMedCrossRefGoogle Scholar
  14. 14.
    Ibsen H, Olsen MH, Wachtell K et al (2005) Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 45:198–202PubMedCrossRefGoogle Scholar
  15. 15.
    Irie F, Iso H, Sairenchi T et al (2006) The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 69:1264–1271PubMedCrossRefGoogle Scholar
  16. 16.
    Leoncini G, Ratto E, Viazzi F et al (2008) Global risk stratification in primary hypertension: the role of the kidney. J Hypertens 26:427–432PubMedCrossRefGoogle Scholar
  17. 17.
    Mancia G, De Backer G, Dominiczak A et al (2007) 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 25:1751–1762PubMedCrossRefGoogle Scholar
  18. 18.
    Matsushita K, Selvin E, Bash LD et al (2009) Change in estimated GFR associates with coronary heart disease and mortality. J Am Soc Nephrol 20:2617–2624PubMedCrossRefGoogle Scholar
  19. 19.
    Parving HH, Lehnert H, Brochner-Mortensen J et al (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870–878PubMedCrossRefGoogle Scholar
  20. 20.
    Perk J, De Backer G, Gohlke H et al (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 33:1635–1701PubMedCrossRefGoogle Scholar
  21. 21.
    Perkovic V, Verdon C, Ninomiya T et al (2008) The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med 5:e207PubMedCrossRefGoogle Scholar
  22. 22.
    Scheid DC, Mccarthy LH, Lawler FH et al (2001) Screening for microalbuminuria to prevent nephropathy in patients with diabetes: a systematic review of the evidence. J Fam Pract 50:661–668PubMedGoogle Scholar
  23. 23.
    Schmieder RE, Mann JF, Schumacher H et al (2011) Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 22:1353–1364PubMedCrossRefGoogle Scholar
  24. 24.
    Schmieder RE, Schrader J, Zidek W et al (2007) Low-grade albuminuria and cardiovascular risk: what is the evidence? Clin Res Cardiol 96:247–257PubMedCrossRefGoogle Scholar
  25. 25.
    Sciarretta S, Valenti V, Tocci G et al (2010) Association of renal damage with cardiovascular diseases is independent of individual cardiovascular risk profile in hypertension: data from the Italy – Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. J Hypertens 28:251–258PubMedCrossRefGoogle Scholar
  26. 26.
    Sehestedt T, Jeppesen J, Hansen TW et al (2010) Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J 31:883–891PubMedCrossRefGoogle Scholar
  27. 27.
    Volpe M, Battistoni A, Tocci G et al (2012) Cardiovascular risk assessment beyond systemic coronary risk estimation: a role for organ damage markers. J Hypertens 30:1056–1064PubMedCrossRefGoogle Scholar
  28. 28.
    Weiner DE, Tabatabai S, Tighiouart H et al (2006) Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis 48:392–401PubMedCrossRefGoogle Scholar
  29. 29.
    Yuyun MF, Khaw KT, Luben R et al (2004) Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol 33:189–198PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Medizinische Klinik 4, Nephrologie und HypertensiologieUniversitätsklinikum ErlangenErlangenDeutschland
  2. 2.Institut für Pharmakologie und präventive Medizin GmbHBlankenfelde-MahlowDeutschland

Personalised recommendations